Cambrex Corporation

Cambrex Corporation is a Contract Development Manufacturing Organisation (CDMO) that provides drug substance, drug product and analytical services across the entire drug lifecycle, as well as active pharmaceutical ingredients (APIs).

Cambrex Corporation
TypePrivate
IndustryPharmaceuticals
FoundedNew Jersey (1981)
HeadquartersEast Rutherford, NJ
Key people
Steven M. Klosk, CEO, President,
Revenue 534.7 million USD (2017)
57.2 million USD (2015)
Total assets 505.5 million USD (2015)
Total equity 310.8 million USD (2015)
Number of employees
2,100+
Websitecambrex.com

Cambrex has cGMP manufacturing facilities in the US (Agawam, MA; Charles City, IA; Durham, NC; High Point, NC; Longmont, CO; Whippany, NJ), Canada (Mirabel, Québec) and Europe (Edinburgh, UK; Karlskoga, Sweden, Milan, Italy, and R&D centers in Tallinn, Estonia, Wiesbaden, Germany). The headquarters are located in East Rutherford, NJ.

In 2007, Cambrex divested their biologics business to Lonza to focus on small molecule APIs.[1]

History

Cambrex was founded in 1981, when the CasChem group acquired the castor oil and derivatives product lines from NL Industries. In 1987, CasChem was renamed Cambrex Corporation and became listed on NASDAQ. Cambrex entered the pharmaceutical market in 1994 with the acquisition of Nobel Pharma Chemistry business, now known as Cambrex Karlskoga AB and Cambrex Profarmaco.

Through multiple acquisitions during the late 1990s, the firm entered the bioscience and the chiral enzymatic catalyst markets. In 1998, Cambrex was listed on the NYSE. The firm acquired two contract biopharmaceutical manufacturing facilities, in 2001, to bulk manufacture biologics and pharmaceutical ingredients from clinical to commercial scales. In 2007, the firm decided to focus on its core competencies and sold the biologics business to Lonza Group. In 2008, Prosyntest (now Cambrex Tallinn) was acquired, and Steve Klosk was appointed CEO, while remaining President. To broaden their biocatalysis platform, Cambrex acquired IEP, now known as Cambrex IEP. In 2014, they acquired Zenara Pharma to enhance its drug product formulation capabilities, including Nicotine Replacement Therapy products. Cambrex Corporation has agreed to acquire Pharma Core Inc, a private company specializing in developing, manufacturing and scaling up small molecule APIs for clinical phase projects, for approx $25 million [2]

In 2018, Cambrex acquired Halo Pharma for $425 million.[3]

In 2019, Cambrex acquired Avista Pharma Solutions for $252m to become a fully integrated CDMO.[4]

References
  1. "Cambrex acquires biopharmaceutical production business of Bio Science Contract Production". www.pharmaceuticalonline.com. Retrieved 2020-01-22.
  2. "Cambrex to acquire API manufacturer in US". WorldOfChemicals. Sep 30, 2016. Retrieved September 30, 2016.
  3. Corporation, Cambrex (2018-09-12). "Cambrex Completes Acquisition of Halo Pharma". GlobeNewswire News Room. Retrieved 2020-05-18.
  4. outsourcing-pharma.com. "Cambrex acquires Avista for $252m, becomes integrated CDMO". outsourcing-pharma.com. Retrieved 2020-05-18.
    • Historical business data for Cambrex Corporation:
    • SEC filings
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.